AVENIO Tumor Tissue Targeted Kit – Tumor Profiling

Material Number: Select a variation

Next-generation sequencing (NGS) liquid biopsy assay specially designed to monitor tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease (MRD). Contains 471 frequently mutated regions associated with the presence of disease across 197 genes.

The AVENIO Tumor Tissue Targeted Kit is a next-generation sequencing (NGS) assay for comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples.  It contains 17 guideline-aligned biomarkers, including those in the U.S. National Comprehensive Cancer Network (NCCN) 1.


  • Panel size: 81 kb
  • Sample size: 2×19 µm FFPET curls/sections
  • DNA input 20 ng of amplifiable DNA
  • Reactions per kit: 24

Turn-around time: 5 days from extraction to results

The present kits include the following subkits:

* Based on the plate you choose.

For more information or further assistance, please reach out to our local representative through the contact form.

: Table demonstrating the performance of AVENIO Tumor Tissue Analysis kitsAVENIO Tumor Tissue Targeted Kit is a part of the AVENIO family of NGS oncology assays that include three tumor tissue and three corresponding ctDNA assays. By using the wider family of AVENIO assays, labs can obtain detailed molecular findings across all four mutation classes from tissue or plasma samples. 





  1. National Comprehensive Cancer Network. October 15, 2016
  2. Data on file.